Compare Hasbro, Inc. (HAS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Sanofi SA — how do they compare? Hasbro, Inc. trades at $92.69 (market cap $12.80B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 7.6× Hasbro, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Sanofi SA for 94 Days on average.
| HAS | SNY | |
|---|---|---|
Market Cap | $12.80B | $96.81B |
Volume | 1,356,688 | 2,081,815 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $52.34 |
52-Week Low | $70.95 | $39.51 |
Typical Hold Time | 97 Days | 94 Days |
Enterprise Value | $14.99B | $116.20B |
Dividend Yield | 3.09% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $92.50, up 1.61% today, with a bullish technical outlook and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 20, 2026. Revenue is projected to grow to $5.0B in 2026, with net income rebounding to $794M. The company maintains a solid gross profit margin of 64.41% and positive operating cash flow, though it carries significant long-term debt of $3.38B.
The outlook is positive, driven by earnings momentum and cost-saving initiatives, but risks include high debt levels and competitive pressures. Analyst price targets suggest upside potential, with a consensus target of $107.60. Investors should monitor the upcoming earnings report for confirmation of growth trends and debt management progress.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
